Key Points
- Director Milton Ault III bought 108,388 shares at $1.00 on April 14, raising his direct stake to 116,648 shares — a 1,312.2% increase — in a $108,388 SEC‑filed transaction.
- Alzamend Neuro is a micro‑cap biopharma (market cap ≈ $3.8M) trading near $1.00 with negative recent results (Q4 EPS -$0.58) and a 12‑month range of $0.84–$8.22.
- Analyst coverage is thin and mixed (one Buy, one Sell; average price target $28), while institutional investors own about 49.6% and Geode Capital recently raised its stake to 27,506 shares.
Alzamend Neuro, Inc. (NASDAQ:ALZN - Get Free Report) Director Milton Ault III acquired 108,388 shares of the company's stock in a transaction on Tuesday, April 14th. The stock was acquired at an average price of $1.00 per share, for a total transaction of $108,388.00. Following the purchase, the director directly owned 116,648 shares of the company's stock, valued at approximately $116,648. This trade represents a 1,312.20% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Alzamend Neuro Stock Down 2.0%
NASDAQ:ALZN opened at $1.00 on Friday. The stock's 50 day moving average price is $1.64 and its two-hundred day moving average price is $2.04. The firm has a market capitalization of $3.80 million, a price-to-earnings ratio of -0.46 and a beta of -0.05. Alzamend Neuro, Inc. has a 12-month low of $0.84 and a 12-month high of $8.22.
Alzamend Neuro (NASDAQ:ALZN - Get Free Report) last released its quarterly earnings data on Wednesday, March 11th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.05). Equities research analysts expect that Alzamend Neuro, Inc. will post -1.68 EPS for the current year.
Analysts Set New Price Targets
ALZN has been the topic of a number of recent research reports. Ascendiant Capital Markets lowered their target price on Alzamend Neuro from $42.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, December 22nd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Alzamend Neuro in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $28.00.
Check Out Our Latest Analysis on ALZN
Hedge Funds Weigh In On Alzamend Neuro
A hedge fund recently raised its stake in Alzamend Neuro stock. Geode Capital Management LLC lifted its position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN - Free Report) by 33.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,506 shares of the company's stock after purchasing an additional 6,928 shares during the period. Geode Capital Management LLC owned 0.72% of Alzamend Neuro worth $50,000 as of its most recent filing with the Securities and Exchange Commission. 49.61% of the stock is currently owned by institutional investors.
About Alzamend Neuro
(
Get Free Report)
Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
